文献速递慢阻肺

长效支气管舒张剂联合治疗与COPD患者主要心血管不良事件风险:系统评价与荟萃分析

Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis.
PubMed 文献 · Eur Respir J · 2023-02-09

结果显示,与ICS/LABA相比,LAMA/LABA双联治疗(RR 1.42,95%CI 1.11-1.81)和三联治疗(RR 1.29,95%CI 1.03-1.61)均显著增加MACE风险,在基线MACE年风险>1%的试验中尤为明显。

要点

  • 与ICS/LABA相比,LAMA/LABA双联治疗显著增加COPD患者MACE风险(RR 1.42,95%CI 1.11-1.81)。
  • 与ICS/LABA相比,三联治疗同样显著增加MACE风险(RR 1.29,95%CI 1.03-1.61)。
  • 基线MACE年风险>1%的试验中风险增加最明显,临床决策需权衡症状与急性加重获益。

核心结论

  • 与ICS/LABA相比,LAMA/LABA双联或三联治疗增加COPD患者心血管风险,尤其基线MACE年风险>1%者。

主要发现

  • 双联LAMA/LABA的MACE发生率为1.6% vs 1.3%,相对风险1.42(95%CI 1.11-1.81)。
  • 三联治疗的MACE发生率为1.6% vs 1.4%,相对风险1.29(95%CI 1.03-1.61)。
  • 与单用LAMA、单用LABA或安慰剂相比,双联LAMA/LABA未显著增加MACE风险,但比较可能缺乏足够统计效能。
  • 基线MACE年平均风险>1%的随机对照试验中超额风险最明显。

关键数值与推荐

  • 主要结局MACE为心血管死亡、心肌梗死或卒中的复合终点。

临床怎么用

  • 对基线MACE年风险>1%的COPD患者,选择LAMA/LABA或三联治疗时应权衡症状与急性加重获益及心血管风险。

局限性

  • 与单用LAMA、单用LABA或安慰剂的比较可能缺乏足够统计效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Accumulated high-quality data from randomised controlled trials (RCTs) indicate that long-acting muscarinic antagonist (LAMA)/long-acting β2 agonist (LABA) combination therapy significantly improves clinical symptoms and health status in patients with chronic obstructive pulmonary disease (COPD) and reduces exacerbation risk. However, there is a growing concern that LAMA/LABA therapy may increase the risk of cardiovascular disease in patients with COPD. The aim of this paper is to determine whether the use of LAMA/LABA combination therapy modifies the risk of cardiovascular disease in patients with COPD. METHODS: Two reviewers independently searched Embase, PubMed and Cochrane Library to identify relevant RCTs of LAMA/LABA or LABA/LAMA/inhaled corticosteroids (ICS) for the management of patients with COPD that reported on cardiovascular end-points. The primary outcome was major adverse cardiovascular events (MACE), which was a composite of cardiovascular death, myocardial infarction or stroke. RESULTS: A total of 51 RCTs enrolling 91 021 subjects were analysed. Both dual LAMA/LABA (1.6% versus 1.3%; relative risk 1.42, 95% CI 1.11-1.81) and triple therapy (1.6% versus 1.4%; relative risk 1.29, 95% CI 1.03-1.61) significantly increased the risk of MACE compared with ICS/LABA. The excess risk was most evident in RCTs in which the average underlying baseline risk for MACE was >1% per year. Compared with LAMA only, LABA only or placebo, dual LAMA/LABA therapy did not significantly increase the risk of MACE, though these comparisons may have lacked sufficient statistical power. CONCLUSION: Compared with ICS/LABA, dual LAMA/LABA or triple therapy increases cardiovascular risk in patients with COPD. This should be considered in the context of the incremental benefits of these therapies for symptoms and exacerbation rates in patients with COPD, especially in those with a MACE risk of >1% per year.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Yang, Li, Jiang, et al. Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis. Eur Respir J. 2023. PMID: 36137586. doi:10.1183/13993003.00302-2022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。